Providence Capital Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.77M | Sell |
18,952
-28
| -0.1% | -$6.02K | 0.72% | 53 |
|
|
2026
Q1 | $4.13M | Buy |
18,980
+442
| +2% | +$98K | 0.67% | 62 |
|
|
2025
Q4 | $4.24M | Buy |
18,538
+621
| +3% | +$141K | 0.71% | 58 |
|
|
2025
Q3 | $4.15M | Buy |
17,917
+465
| +3% | +$94.7K | 0.72% | 52 |
|
|
2025
Q2 | $3.24M | Buy |
17,452
+980
| +6% | +$182K | 0.59% | 65 |
|
|
2025
Q1 | $3.45M | Buy |
16,472
+204
| +1% | +$39.7K | 0.72% | 58 |
|
|
2024
Q4 | $2.89M | Buy |
16,268
+49
| +0.3% | +$9.01K | 0.59% | 68 |
|
|
2024
Q3 | $3.2M | Buy |
16,219
+118
| +0.7% | +$22K | 0.64% | 66 |
|
|
2024
Q2 | $2.76M | Buy |
16,101
+169
| +1% | +$28K | 0.6% | 68 |
|
|
2024
Q1 | $2.9M | Buy |
15,932
+184
| +1% | +$31.7K | 0.63% | 66 |
|
|
2023
Q4 | $2.44M | Sell |
15,748
-489
| -3% | -$71.3K | 0.59% | 68 |
|
|
2023
Q3 | $2.42M | Buy |
16,237
+106
| +0.7% | +$15.6K | 0.63% | 68 |
|
|
2023
Q2 | $2.17M | Buy |
16,131
+365
| +2% | +$53.5K | 0.55% | 72 |
|
|
2023
Q1 | $2.51M | Buy |
15,766
+576
| +4% | +$88.1K | 0.66% | 64 |
|
|
2022
Q4 | $2.45M | Buy |
15,190
+9
| +0.1% | +$1.38K | 0.66% | 68 |
|
|
2022
Q3 | $2.04M | Buy |
15,181
+302
| +2% | +$43.3K | 0.61% | 75 |
|
|
2022
Q2 | $2.28M | Sell |
14,879
-5,348
| -26% | -$817K | 0.66% | 76 |
|
|
2022
Q1 | $3.26M | Sell |
20,227
-3,057
| -13% | -$444K | 0.8% | 55 |
|
|
2021
Q4 | $3.15M | Buy |
23,284
+995
| +4% | +$118K | 0.87% | 50 |
|
|
2021
Q3 | $2.4M | Buy |
22,289
+7,075
| +47% | +$808K | 0.75% | 54 |
|
|
2021
Q2 | $1.71M | Buy |
15,214
+800
| +6% | +$90.1K | 0.55% | 66 |
|
|
2021
Q1 | $1.56M | Buy |
14,414
+689
| +5% | +$73.7K | 0.57% | 66 |
|
|
2020
Q4 | $1.47M | Buy |
13,725
+1,532
| +13% | +$147K | 0.6% | 64 |
|
|
2020
Q3 | $1.07M | Buy |
12,193
+509
| +4% | +$47.9K | 0.56% | 63 |
|
|
2020
Q2 | $1.15M | Buy |
+11,684
| New | +$1.03M | 0.65% | 60 |
|
|
2020
Q1 | – | Sell |
-116
| Closed | -$10K | – | 236 |
|
|
2019
Q4 | $10K | Buy |
+116
| New | +$9.63K | 0.01% | 176 |
|
|
2018
Q1 | – | Sell |
-150
| Closed | -$15K | – | 244 |
|
|
2017
Q4 | $15K | Buy |
+150
| New | +$14.1K | 0.01% | 172 |
|
Other funds holding ABBV
Providence Capital Advisors's ABBV Position: Q2 2026 in Review
Providence Capital Advisors reduced its AbbVie (ABBV) stake by 0.15% in Q2 2026, selling an estimated $6.02K and leaving 18,952 shares worth $4.77M. The position accounts for 0.72% of the portfolio, ranked #53.
Providence Capital Advisors first reported a position in ABBV in Q4 2017 and has held it in 27 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Providence Capital Advisors held 18,952 shares of AbbVie worth $4.77M as of Q2 2026.
- Providence Capital Advisors sold 28 AbbVie shares in Q2 2026, an estimated $6.02K.
- AbbVie made up 0.72% of Providence Capital Advisors's portfolio in Q2 2026, its #53 holding.
- Providence Capital Advisors first reported a position in AbbVie in Q4 2017 and has held it in 27 quarters since.
- 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Providence Capital Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.